EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment for HER2-ultralow Breast Cancer

New indication concerns the management of adult patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer

Source